

infection and be used to treat HAV infected patients; development of transgenic animals for HAV vaccine production and testing.

HAVcr-1 has recently been molecularly cloned and its cDNA is available for further development. A Notice of Allowance has recently been issued on this case by the U.S. Patent and Trademark Office; foreign rights are also available. This invention is available for licensing on an exclusive or nonexclusive basis.

Dated: January 9, 1997.

Barbara M. McGarey,  
Deputy Director, Office of Technology Transfer.

[FR Doc. 97-1532 Filed 1-21-97; 8:45 am]

BILLING CODE 4140-01-M

### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

**ADDRESS:** Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting the indicated licensing specialist at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

2,2'-Bipyridyl, a Ferrous Chelator, Prevents Vasospasm in a Primate Model of Subarachnoid Hemorrhage

LL Horky (NINDS)

Serial No. 08/672,060 filed 26 Jun 96

Licensing Contact: Stephen Finley, Ph.D., 301/496-7735 ext 215

Subarachnoid hemorrhage (SAH) occurs in 28,000 people per year in North America. Symptomatic vasospasm occurs in the majority of individuals suffering SAH and is the most common cause of morbidity and mortality in patients reaching neurological care. Specifically, vasospasm causes cerebral ischemia or

stroke, and the prevention of vasospasm could prevent stroke and death as well as allow physicians more freedom in scheduling surgery when the operative risks are lower.

Intravenous administration of 2,2'-bipyridyl successfully prevented vasospasm in a reliable primate model of subarachnoid hemorrhage. Bipyridyl may provide a safe, cost-effective and reliable therapy for vasospasm in the clinical setting. Additional ferrous chelates, which may also prove effective, are also embodied in the invention. (portfolio: Central Nervous System—Therapeutics, neurological, stroke)

Interleukin-4 Stimulated T-Lymphocyte Cell Death for the Treatment of Autoimmune Diseases, Allergic Disorders and Graft Rejection

MJ Lenardo, SA Boehme, J Critchfield (NIAID)

Serial No. 08/348,286 filed 30 Nov 94

Licensing Contact: Jaconda Wagner, J.D., 301/496-7735 ext 284

The discovery that interleukin-4 (IL-4) predisposes T lymphocytes to programmed cell death (apoptosis) allows for a novel method of therapeutic intervention in diseases caused by the action of IL-4-responsive T cells. Specifically, the therapy induces the death of a subpopulation of T lymphocytes that are capable of causing disease. Current therapies may cause general death or suppression of immune responses involving T-cells, severely comprising a patient's immune system. This treatment affects only the subset of T cells that react with a specified antigen, thereby leaving a patient's immune system uncompromised. This invention is useful in treating allergies and HIV complications. Both fields are available for licensing (portfolio: Internal Medicine—Therapeutics, anti-inflammatory)

Interleukin-2 Stimulated T-Lymphocyte Cell Death for the Treatment of Autoimmune Diseases, Allergic Disorders and Graft Rejection

MJ Lenardo (NIAID)

Serial No. 08/482,724 filed 07 Jun 95

Licensing Contact: Jaconda Wagner, J.D., 301/496-7735 ext 284

T-Cell apoptosis induced by administration of IL-2 and antigen offers an important new treatment for allergic disorders, which are due to the effects of antigen-activated T-cells. Antigen-activated T-cells cause the release of harmful lymphokines and the production of immunoglobulin E by B cells. Presently available methods for

treating allergies have limitations because they are nonspecific in their action and have side effects and limited efficacy. IL-2 and antigen stimulates the programmed death of only antigen-specific T-cells while leaving the rest of the patient's T-cells and other immune cells intact. This invention is also useful in treating HIV. Both fields of use, allergies and HIV, are available for licensing. (portfolio: Internal Medicine—Therapeutics, anti-inflammatory)

Dated: January 13, 1997.

Barbara M. McGarey,  
Deputy Director, Office of Technology Transfer.

[FR Doc. 97-1534 Filed 1-21-97; 8:45 am]

BILLING CODE 4140-01-M

### Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Behavioral and Neurosciences.

*Date:* January 20, 1997.

*Time:* 3:30 p.m.

*Place:* NIH, Rockledge 2, Room 5168 Telephone Conference.

*Contact Person:* Dr. Jane Hu, Scientific Review Administrator, 6701 Rockledge Drive, Room 5168, Bethesda, Maryland 20892, (301) 435-1245.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* February 4, 1997.

*Time:* 2:00 p.m.

*Place:* NIH, Rockledge 2, Room 6170 Telephone Conference.

*Contact Person:* Dr. Dennis Leszczyski, Scientific Review Administrator, 6701 Rockledge Drive, Room 6170, Bethesda, Maryland 20892, (301) 435-1044.

*Name of SEP:* Multidisciplinary Sciences.

*Date:* February 24-26, 1997.

*Time:* 8:00 a.m.

*Place:* Doubletree Hotel, Rockville, Maryland.

*Contact Person:* Dr. Dharam Dhindsa, Scientific Review Administrator, 6701 Rockledge Drive, Room 5206, Bethesda, Maryland 20892, (301) 435-1174.

*Name of SEP:* Clinical Sciences.

*Date:* February 24-26, 1997.

*Time:* 8:30 a.m.

*Place:* Hyatt Regency, Bethesda, Maryland.

*Contact Person:* Dr. Christine Melchior, Scientific Review Administrator, 6701 Rockledge Drive, Room 4118, Bethesda, Maryland 20892, (301) 435-1713.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* February 26, 1997

*Time:* 6 p.m.

*Place:* Doubletree Hotel, Rockville, Maryland.

*Contact Person:* Dr. Sooja Kim, Scientific Review Administrator, 6701 Rockledge Drive, Room 4120, Bethesda, Maryland 20892, (301) 435-1780.

*Name of SEP:* Multidisciplinary Sciences.

*Date:* March 5-7, 1997

*Time:* 8:00 a.m.

*Place:* Doubletree Hotel, Rockville, Maryland.

*Contact Person:* Dr. Bill Bunnag, Scientific Review Administrator, 6701 Rockledge Drive, Room 5212, Bethesda, Maryland 20892, (301) 435-1177.

*Name of SEP:* Clinical Sciences.

*Date:* March 10-11, 1997.

*Time:* 8:30 a.m.

*Place:* Bethesda Marriott Hotel, Bethesda, MD.

*Contact Person:* Dr. Nancy Shinowara, Scientific Review Administrator, 6701 Rockledge Drive, Room 5216, Bethesda, Maryland 20892, (301) 435-1173.

*Name of SEP:* Multidisciplinary Sciences.

*Date:* March 27-28, 1997.

*Time:* 6:00 p.m.

*Place:* Courtyard by Marriott, Rochester, New York.

*Contact Person:* Dr. Bill Bunnag, Scientific Review Administrator, 6701 Rockledge Drive, Room 5212, Bethesda, Maryland 20892, (301) 435-1177.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 15, 1997.

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*

[FR Doc. 97-1535 Filed 1-21-97; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4200-N-08]

### Notice of Proposed Information Collection for Public Comment

**AGENCY:** Office of the Assistant Secretary for Policy Development and Research, HUD.

**ACTION:** Notice

**SUMMARY:** The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act of 1995, Public Law 104-13 (44 U.S.C. 3506(c)(2)(A)). The Department is soliciting public comments on the subject proposal.

**DATES:** Comments due: Written comments must be submitted on or before March 24, 1997.

**ADDRESSES:** Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Reports Liaison Officer, Office of Policy Development and Research, Department of Housing and Urban Development, 451 7th Street, SW, room 8226, Washington, DC 20410.

**FOR FURTHER INFORMATION CONTACT:** Ronald J. Sepanik at (202)-708-1060, Ext. 334 (this is not a toll-free number), or Linda P. Hoyle, Bureau of the Census, Manufacturing and Construction Division, room 2105, FOB 4, Washington, DC 20233-6900, (301) 457-1321.

**SUPPLEMENTARY INFORMATION:** The Department will submit the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended).

This Notice is soliciting comments from members of the public and affected agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information

technology, e.g., permitting electronic submission of responses.

This Notice also lists the following information:

*Title of Proposal:* Survey of Manufactured (Mobile) Home Placements.

*OMB Control Number:* 2528-0029.

*Description of the need for the information and proposed use:* The Survey of Manufactured (Mobile) Home Placements collects data on the characteristics of newly manufactured homes placed for residential use including number, sales price, location, and other selected characteristics. HUD uses the statistics to respond to a Congressional mandate in the Housing and Community Development Act of 1980, 42 U.S.C. 5424 note, which requires HUD to collect and report mobile home sales and price information for the nation, census regions, states, and selected metropolitan areas and to monitor whether new manufactured homes are being placed on owned rather than rented lots. HUD also used these data to monitor total housing production and its affordability.

Data

*Agency Form Numbers:* C-MH-9A, C-MH-9B.

*Members of affected public:* Business firms or other for-profit institutions.

Estimation of the total numbers of hours needed to prepare the information collection including number of respondents, frequency of response, and hours of response:

*Number of respondents:* 4,000.

*Estimate Responses per Respondent:*

2.

*Time per respondent:* 30 minutes.

*Total hours to respond:* 4,000.

*Respondent's Obligation:* Voluntary.

*Status of the proposed information collection:* Pending OMB approval.

Authority: Title 42 U.S.C. 5424 note, Title 13 U.S.C. Section 8(b), and Title 12, U.S.C., Section 1701z-1.

Dated: January 10, 1997.

Lawrence L. Thompson,  
*General Deputy Assistant Secretary, Office of Policy Development and Research.*

[FR Doc. 97-1457 Filed 1-21-97; 8:45 am]

BILLING CODE 4210-62-M

[Docket No. FR-4200-N-06]

### Notice of Proposed Information Collection for Public Comments

**AGENCY:** Office of the Assistant Secretary for Public and Indian Housing, HUD.

**ACTION:** Notice.